Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 15 Immunology (elisa) PhD Projects, Programmes & Scholarships

Discipline

Discipline

Biological Sciences

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


Immunology (elisa) PhD Projects, Programmes & Scholarships

We have 15 Immunology (elisa) PhD Projects, Programmes & Scholarships

Diagnostics for FMF patients and carrier survival in pandemics

Background. Familial Mediterranean Fever (FMF) is a rare inherited genetic disease where patients acquire a mutation on the pyrin gene leading to excessive inflammasome activation and excessive inflammation. Read more

Manipulation of neuroimmune responses and behaviour by infectious agents

This project is available exclusively to self-funded students who wish to commence study for a PhD in the academic year 2023/24. The project focuses on how infectious agents modify the individuals that they infect and how neuroimmune responses to infection moderate behaviour changes in warm-blooded animals and humans. Read more

Investigating the metabolic link between leukaemia and heart failure (RUSHWORTHS_U24BIGC)

Primary supervisor - Dr Stuart Rushworth. Secondary supervisor - Dr James Smith. Rushworth Lab. This 4-year PhD project funded by the Big C cancer charity represents an exciting opportunity to develop and conduct research at the forefront of cancer research. Read more

SLS 3: Investigating the anti-inflammatory effects of artemisinin compounds on macrophages under systemic inflammatory conditions

Artemisinin compounds are safe and effective antimalarials. Recent evidence in our lab has shown these compounds also exert a potent anti-inflammatory effect by inhibiting neutrophil migration and the release of cytokines, chemokines and neutrophil extracellular traps. Read more

Cancer: Understanding the immunosuppressive role of fibroblast and macrophages in Breast cancer

Oncolytic viruses (OVs) preferentially infect and kill cancer cells, and their clinical efficacy has been demonstrated against a number of different cancers. The most clinically advanced OV is a genetically engineered herpes simplex virus (T-VEC) which expresses GMCSF to aid the development of anti-tumour immune responses; T-VEC is approved for the treatment of metastatic melanoma. Read more
  • 1

Filtering Results